Based on these pieces of evidence, the mutation of ARID1A and/or the loss of expression of BAF250a may appear as a promising strategy for molecular diagnosis of endometriosis-associated ovarian cancer [343]. This evidence concerns the gene ARID1A and ovarian cancer.